Whitepaper: The impacts of Brexit on the bio/pharmaceutical industry
On 23 June 2016, the decision was made on the European Union referendum for the United Kingdom to withdraw from the European Union.
List view / Grid view
On 23 June 2016, the decision was made on the European Union referendum for the United Kingdom to withdraw from the European Union.
A market report on the aspirin enteric-coated pharmaceutical industry outlines current trends and opportunities for growth from 2018 until 2023...
The FDA requires drugs to be tested on children after they have been approved for adults, however two thirds of these are not happening...
The next five years will see game-changing improvements made in upstream, downstream and continuous bioprocessing, predicts one industry specialist...
18 September 2018 | By Clarivate Analytics
In 2017 the WHO estimated that the counterfeit drug market represents around 10-15 percent of the pharmaceutical market worldwide, with an estimated $200bn revenue per year. Worldwide there were 3,509 pharmaceutical crime incidents in 2017, which represents an 11% increase from 2016. Most falsified medicines that reach the market do…
The global pharmaceutical industry has been expanding steadily at varying rates of regional growth; the pace of growth being relatively slow in the developed, matured markets but rapid in developing nations...
Improving data integrity is the aim of a new guide published by the Russian State Institute for Drugs and Good Practices in collaboration with consultancy PQE Group...
The NHS has announced a groundbreaking new treatment, CAR-T, for children with leukaemia...
Researchers have outlined a simple method to increase the number of injection-drug taking individuals with HIV to adhere to their medication...
Researchers found that more than one quarter (26 per cent) of patients taking Aimovig 70mg were migraine free after month 15...
A trade deal between the UK and USA could risk increasing drug prices in the UK, which could diminish the affordability and accessibility of the NHS...
The U.S. Food and Drug Administration has approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment.
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study.
The FDA has approved Lutathera for the treatment of a type of cancer that affects the pancreas the gastrointestinal tract...
The EMA has granted a Marketing Authorization for Zubsolv, a novel rapidly-disintegrating treatment option for opioid dependence...